Detección fenotípica (Spanish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Detección fenotípica" in Spanish language version.

refsWebsite

Global rank Spanish rank

2^nd place

4^th place

6^th place

5^th place

149^th place

128^th place

low place

low place

1^st place

low place

archive.org

«Phenotypic screening, take two». Science-Business EXchange 5 (15): 380. April 2012. doi:10.1038/scibx.2012.380.
«Modern phenotypic drug discovery is a viable, neoclassic pharma strategy». J. Med. Chem. 55 (10): 4527-38. May 2012. PMID 22409666. doi:10.1021/jm201649s.
«How were new medicines discovered?». Nat Rev Drug Discov 10 (7): 507-19. July 2011. PMID 21701501. doi:10.1038/nrd3480.
Barrett MJ, Frail DE, ed. (2012). «PhenotypicIn VivoScreening to Identify New, Unpredicted Indications for Existing Drugs and Drug Candidates». Drug repositioning: Bringing new life to shelved assets and existing drugs. Hoboken, NJ: John Wiley & Sons. pp. 253-290. ISBN 978-0-470-87827-9. doi:10.1002/9781118274408.ch9.
«Exploiting complexity and the robustness of network architecture for drug discovery». J. Pharmacol. Exp. Ther. 325 (1): 1-9. April 2008. PMID 18202293. doi:10.1124/jpet.107.131276.
«A critique of the molecular target-based drug discovery paradigm based on principles of metabolic control: advantages of pathway-based discovery». Metab. Eng. 10 (1): 1-9. January 2008. PMID 17962055. doi:10.1016/j.ymben.2007.09.003.
«theraTRACE®: A mechanism unbiased in vivo platform for phenotypic screening and drug repositioning». Drug Discovery Today: Therapeutic Strategies 8 (2): 89-95. 2011. doi:10.1016/j.ddstr.2011.06.002.

«Open Innovation Drug Discovery - What are PD2 and TargetD2?». Eli Lilly & Company. Archivado desde el original el 30 de enero de 2012. Consultado el 4 de junio de 2012.

«Modern phenotypic drug discovery is a viable, neoclassic pharma strategy». J. Med. Chem. 55 (10): 4527-38. May 2012. PMID 22409666. doi:10.1021/jm201649s.
«How were new medicines discovered?». Nat Rev Drug Discov 10 (7): 507-19. July 2011. PMID 21701501. doi:10.1038/nrd3480.
«Exploiting complexity and the robustness of network architecture for drug discovery». J. Pharmacol. Exp. Ther. 325 (1): 1-9. April 2008. PMID 18202293. doi:10.1124/jpet.107.131276.
«A critique of the molecular target-based drug discovery paradigm based on principles of metabolic control: advantages of pathway-based discovery». Metab. Eng. 10 (1): 1-9. January 2008. PMID 17962055. doi:10.1016/j.ymben.2007.09.003.

«Open Innovation Drug Discovery - What are PD2 and TargetD2?». Eli Lilly & Company. Archivado desde el original el 30 de enero de 2012. Consultado el 4 de junio de 2012.